MAIL MAN

[righty]

From: OTCJournal

Up, Up, and Away: China Recycling Tears Up Chart



There wasn't much to not like about yesterday's price and volume surge in China Recycling Energy (OTC BB: CREG). It was strong. Yesterday's action not only marked the highest price in the stock's history, but it also marked the highest one day volume in the stock's history.

We've now notched a solid gain of 35% on this one since I introduced it back on October 19th at $2.40 with a $5 price target.

The news earlier this week might help explain the recent move in the stock. Another explanation isn't quite as visible, but, of course, I have it for you. Let's start with Tuesday's news concerning a $26.7 million loan to the Low Carbon Fortune-Energy Recycling No. 1 Collective Capital Trust Plan.

This is a trust that was formed to finance energy saving technology installations for Erdos Power- a CREG client. You can read the release by clicking here, but let me simplify it for you. Erdos needed financing to complete the installation of the CREG technology, which is a BOT (Build, Operate, Transfer) project for CREG. They just got over $27 million to get it done, and with no dilution to CREG shareholders. It was a loan to the trust, and the Trust is CREG's customer. Voila- a gigantic, high margin project with ten years of residual revenues- all paid for with a loan to a separate entity. Ideal. This is what is commonly referred to as "off balance sheet" financing.



Now, here's the part you haven't seen. Chicago based Garwood Securities issued a research report on the company. Director of Research Jackson Spears rates the stock a "buy"- their strongest rating, and projects $4.50 per share for the stock- 38% higher than Thursday's close.

In the report, the ERDOS project is listed as having a total value of $58.6 million when completed, and is listed as an under construction project. Erdos is listed as having 7 phases. In the report Spears states he would like to see how the company plans to "fund its capital needs in 2010 and beyond" for the individual project. It appears the market likes the answer. Spears forecasts CREG will earn $.28 in EPS in 2010. I believe that number is low- it could be more like $.40.

With the recurring revenue model I've written about in past editions, I believe the stock could command a much higher multiple, and therefore my $5 price target stands, and I might even ramp it up as they get more of these projects financed.

In the meantime, despite being somewhat proprietary, I have managed to get a PDF version of their research report, and it's available on the OTC Journal site. To simplify, you can either go to the CREG archive section, or you could just

click here

to read the report.

These ideas are really starting to work out. My #1 pick- China Education (CEU) made a new all time high this week. Tianyin Pharma (TPI) made a new all time high this week, and CREG (my #2 pick) has now followed suit. However, I would venture to say the CREG breakout yesterday was most impressive when one considers it was on huge relative volume. The stock traded both the highest share volume and dollar volume in its history.

Technically, I believe this breakout could be good for another $.30 to $.40 before the stock takes a breather. We'll have to stand by and see.

Home Page : www.otcjournal.com
Email Questions or Comments To: [e-mail]




--------------------------------------------------------------------------------
Refer A Friend


If you find the OTC Journal informative and profitable, please forward our newsletter alert service to like-minded friends and associates who share similar market interests.



--------------------------------------------------------------------------------
Ensure Newsletter Delivery


To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.



--------------------------------------------------------------------------------



Disclaimer
The OTC Journal Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as described below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter, which is owned by MarketByte, LLC also accepts compensation in connection with the dissemination of information regarding the companies featured. This newsletter should not, therefore, be regarded as an independent publication.
Go Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclosure/compensation/section/profile/ for our full profiles and http://www.otcjournal.com/disclosure/compensation/section/alert/ for Trading Alerts. No compensation of any kind was paid for coverage of CREG. The editor and affiliates of MarketByte LLC have invested approximately 82,000 shares with an approximate cost basis of $1.30 per share. Shares can be bought and sold at anytime without notification.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation of an offer to buy or sell any securities mentioned. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

From time to time MarketByte, LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are discouraged by company policy from owning, buying, selling or otherwise trading stock for their own benefit in the companies who appear in the publication unless such activities are specifically disclosed in the newsletter or on the OTC Journal web site. Full disclosure of position changes is updated on the web site weekly.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.

The information found in this profile is protected by the copyright laws of the united states and may not be copied, or reproduced in any way without the expressed, written consent of the editors of otcjournal.com.